Comparative Pharmacology
Head-to-head clinical analysis: DRAXIMAGE MDP 10 versus TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAXIMAGE MDP 10 versus TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT.
DRAXIMAGE MDP-10 vs TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m medronate is a bone-seeking radiopharmaceutical that localizes in areas of bone turnover, binding via chemisorption to hydroxyapatite crystals, allowing scintigraphic imaging of skeletal lesions.
Technetium Tc 99m albumin aggregated is a radiopharmaceutical that localizes in the pulmonary capillary bed by capillary blockade, allowing for lung perfusion imaging. The aggregated albumin particles are trapped in the pulmonary capillaries, and the Tc 99m emits gamma radiation detectable by gamma cameras.
555-1110 MBq (15-30 mCi) intravenously for skeletal imaging; administered 2-3 hours before imaging.
1-4 mCi (37-148 MBq) intravenous injection for lung perfusion imaging. Single dose per imaging session.
None Documented
None Documented
Terminal elimination half-life: 2.5 hours (range 2-3 hours); clinically, allows rapid imaging post-injection.
Physical half-life of Tc-99m is 6.02 hours; biological half-life of aggregated albumin in lungs is 2-4 hours due to enzymatic degradation and clearance.
Renal: 95% within 6 hours; biliary/fecal: <5%.
Renal: 30-40% within 24 hours (free pertechnetate); fecal: <1% (minor); remainder accumulated in reticuloendothelial system with slow release.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical